Benitec Biopharma Ltd ADR (BNTC)
$11.89 -0.43 (-3.49%)| Market Cap | 294.31M |
| Revenue (ttm) | 0.00 |
| Net Income (ttm) | -21.75M |
| EPS (ttm) | N/A |
| PE Ratio | 0.00 |
| Forward PE | N/A |
| Profit Margin | 0.00% |
| Debt to Equity Ratio | 0.00 |
| Volume | 42,309 |
| Avg Vol | 41,156 |
| Day's Range | N/A - N/A |
| Shares Out | 23.45M |
| Stochastic %K | 30% |
| Beta | 0.76 |
| Analysts | Strong Sell |
| Price Target | $25.43 |
Latest News on BNTC
Mar 25, 2025, 8:00 AM EDT - 13 days ago
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
Feb 14, 2025, 8:10 AM EST - 7 weeks ago
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
Nov 26, 2024, 7:00 AM EST - 4 months ago
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
Nov 14, 2024, 4:30 PM EST - 5 months ago
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
Nov 4, 2024, 8:00 AM EST - 5 months ago
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
Oct 17, 2024, 3:35 PM EDT - 6 months ago
Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
Oct 14, 2024, 6:00 AM EDT - 6 months ago
Benitec Biopharma Announces Updated Investor Webcast Information
Sep 26, 2024, 4:30 PM EDT - 6 months ago
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
Sep 18, 2024, 8:00 AM EDT - 7 months ago
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
May 13, 2024, 8:15 AM EDT - 11 months ago
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
Apr 18, 2024, 7:30 AM EDT - 1 year ago
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
Apr 18, 2024, 7:00 AM EDT - 1 year ago
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
Feb 13, 2024, 8:00 AM EST - 1 year ago
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
Nov 17, 2023, 8:00 AM EST - 1 year ago
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
Nov 13, 2023, 8:00 AM EST - 1 year ago
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
Sep 21, 2023, 8:00 AM EDT - 1 year ago
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
Aug 11, 2023, 1:00 PM EDT - 1 year ago
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
Aug 8, 2023, 10:30 PM EDT - 1 year ago
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
Jul 25, 2023, 1:00 PM EDT - 1 year ago
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023
Jun 26, 2023, 8:00 AM EDT - 1 year ago
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
May 15, 2023, 8:00 AM EDT - 2 years ago
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update
May 8, 2023, 8:05 AM EDT - 2 years ago
Benitec Biopharma to Present at the OPMD International Conference
Feb 13, 2023, 8:00 AM EST - 2 years ago
Benitec Biopharma Releases Second Quarter 2023 Financial Results and Provides Operational Update
Jan 23, 2023, 9:48 AM EST - 2 years ago
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program
Nov 10, 2022, 8:00 AM EST - 2 years ago
Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update
Sep 16, 2022, 8:42 AM EDT - 2 years ago
Benitec Biopharma Inc. Announces Closing of $18 Million Underwritten Public Offering
Sep 12, 2022, 10:06 PM EDT - 2 years ago
Benitec Biopharma Inc. Announces Pricing of $18 Million Underwritten Public Offering
Sep 2, 2022, 8:00 AM EDT - 2 years ago
Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update
Sep 20, 2021, 8:00 AM EDT - 3 years ago
Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results
Sep 13, 2021, 3:58 PM EDT - 3 years ago
Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference
Sep 8, 2021, 8:10 AM EDT - 3 years ago
Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022
Sep 8, 2021, 8:05 AM EDT - 3 years ago
Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals
Sep 8, 2021, 8:00 AM EDT - 3 years ago
Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinical Trial to Begin in 2022
Apr 27, 2021, 9:55 PM EDT - 4 years ago
Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million
Apr 27, 2021, 4:44 PM EDT - 4 years ago
Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock
Feb 24, 2021, 9:26 AM EST - 4 years ago
Benitec Biopharma's Gene Therapy For Rare Muscle Disorder Shows Encouraging Action In Animal Studies
Oct 6, 2020, 4:05 PM EDT - 4 years ago
Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
Oct 2, 2020, 9:05 AM EDT - 4 years ago
Benitec Biopharma Announces Pricing of $10.0 Million Public Offering
Sep 23, 2020, 4:54 PM EDT - 4 years ago
Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results
Sep 1, 2020, 8:15 AM EDT - 4 years ago
Benitec Biopharma to present at H.C. Wainwright's 22nd Annual Global Investment Conference